Science & Technology
Annual economic burden of vision loss and eye disorders, including falls, cognitive decline and depression is estimated to be $139 B2 in US and >$500 B3 worldwide
Dry Age-Related Macular Degeneration (AMD) accounts for 90% of AMD cases, affecting over 34 million people globally11. Late stage of this form, Geographic Atrophy (GA), is the leading cause of blindness in people over 5012, and affects 5 million people globally13
The global prevalence of Macular Degeneration is expected to reach 288 million by 2040
Wet AMD, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and
Retinal Vein Occlusion (RVO) account for over 13.7 million patients in US1 and 96 million patients per year worldwide,
Wet Age-Related Macular Degeneration (wAMD)
Edema caused by abnormal vasculature growth which ultimately results in the loss of visual function.
1.1 Million Patients in the US 2
20 Million Patients World Wide 5
Geographic Atrophy (GA)
An advanced stage dry age-related Macular Degeneration (AMD) that causes progressive, irreversible, and significant central loss of vision
1.1 Million Patients in the US 8
16.4 Million Patients World Wide 9
Diabetic Macular Edema
A complication of diabetes that manifests as inflammation, edema and hard exudates in the macula and leads to loss of visual acuity.
1.5 Million Patients in the US 2
21 Million Patients World Wide 4
Secondary to Retinal
Vein Occlusion (RVO)
Characterized by a retinal vein blockage, which selectively leads to edema formation and loss of visual acuity.
1.1 Million Patients in the US 2
16.4 Million Patients World Wide 6
High blood sugar levels cause damage to blood vessels in the retina and blood vessels can swell and leak, stopping blood from passing through and leading to loss of visual acuity.
1.5 Million Patients in the US2
139 Million Patients World Wide3
More Information regarding Retinal Diseases
Retinal diseases are primarily correlated with diabetes and or aging
Vision loss can be rapid and severe if untreated
Abnormal blood vessels that bleed and leak fluid grow under and into the macula, the central part of the retina
Current Standard of Care
Current Standard of Care (SoC) is intravitreal injections of anti-VEGF agents that need to be given as frequently as once a month, for an indefinite period
Intravitreal (IVT) injections of anti-VEGF drugs (Lucentis/ranibizumab from Roche/Genentech or Elyea/aflibercept from Regeneron/Bayer) by a retina specialist once every 1-2 months, into one or both eyes, often for life
Drug cost per injection: $1950+ (not including physician fees) for branded
Due to frequency of injections, which can be as often as once per month, 20-25% of patients do not adhere to intravitreal injection treatments, often leading to devastating consequences 10
Benefit of regular pharmacologic treatment:
Significant recovery of vision and prevention of vision loss, leading to better lives
Optigo Bio's Solution
Address challenges of Current Standard of Care through novel proprietary approach for anti-VEGF treatments to extend longevity.
Reduce injection frequency from 4-12 weeks to 6-12 months
Decrease drug costs through lower injection frequency
Reduce burden on retina specialists through lower injection frequency
Improve patient adherence through lower injection frequency
Decrease burden on clinics through lower injection frequency
Decrease burden on payor through lower volume of reimbursement claims
1. Based on 2015-2020 public filings from Regeneron, Roche and Novartis for combined indications
3. About 30% of all diabetes patients get Diabetes Retinopathy. 2019 there were 463 M patients
4. International Diabetes Information, Diabetes Macular Edema DME Report
7. Market Scope 2019 Retinal Pharmaceuticals Market Report
8. Tufail A, et al. Objective measurement of reading speed and correlation with patient-reported functional reading independence. Presented at the 15th EURETINA Congress, Nice, France, September 17-20, 2015. Accessed November 21, 2019.
9. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
10. Obeid A, et al. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections. JAMA Ophthalmol. 2018 Nov 1;136(11):1251-1269.
11. Schultz N, et al. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther. 2021 Oct;43(10):1792-1818.
14. Wong WL, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. 2014 Feb;2(2):E106-E116